Literature DB >> 12407133

Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.

Barbara A Pelak1, Diane M Citron, Mary Motyl, Ellie J C Goldstein, Gail L Woods, Hedy Teppler.   

Abstract

This study compared the in vitro activities of ertapenem, ceftriaxone, co-amoxiclav, ciprofloxacin and piperacillin-tazobactam against 314 aerobic bacteria and of ertapenem, piperacillin-tazobactam, cefoxitin, ceftriaxone, chloramphenicol, ticarcillin-clavulanate, ampicillin-sulbactam, clindamycin and metronidazole against 500 anaerobic bacteria from 212 patients with acute pelvic infection. Antimicrobial susceptibilities were determined by broth microdilution (aerobes) or agar dilution (anaerobes), following NCCLS guidelines. The most common isolates were Enterobacteriaceae and Peptostreptococcus spp. Ertapenem was the most active drug tested against Enterobacteriaceae (100% susceptible) and anaerobes (99.8% susceptible); the least active agents were co-amoxiclav (79% of Enterobacteriaceae susceptible) and ceftriaxone (85.9% of anaerobes susceptible). All agents tested had excellent activity against beta-haemolytic streptococci and methicillin-susceptible Staphylococcus aureus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407133     DOI: 10.1093/jac/dkf203

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Authors:  Alan R Noel; Karen E Bowker; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 2.  Ertapenem: a review of its use in the treatment of bacterial infections.

Authors:  Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Ertapenem: a review of its use in the management of bacterial infections.

Authors:  Monique Curran; Dene Simpson; Caroline Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.